Hydrochloric Acid → (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-Acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid hydrochloride
反応式
[C:1]([N:4]1[CH2:9][CH2:8][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:6][CH2:5]1)(=[NH:3])[CH3:2].[ClH:33]>O>[ClH:33].[C:1]([N:4]1[CH2:5][CH2:6][N:7]([C:10]([C@@H:12]2[CH2:16][C@H:15]([S:17][C:18]3[C@H:19]([CH3:32])[C@@H:20]4[C@@H:27]([C@H:28]([OH:30])[CH3:29])[C:26](=[O:31])[N:21]4[C:22]=3[C:23]([OH:25])=[O:24])[CH2:14][NH:13]2)=[O:11])[CH2:8][CH2:9]1)(=[NH:3])[CH3:2]参加物
4
反応物 2
生成物 1
試薬・触媒・溶媒 1
実験手順
200 mg of (1R, 5S, 6S)-2-[(2S, 4S)-2-(4-acetimidoylpiperazin-1-ylcarbonyl)pyrrolidin-4-ylthio]-6-[(1R)-1-hydroxyethyl]-1-methyl-1-carbapen-2-em-3-carboxylic acid [prepared as described in step (b) above] were dissolved in 5 ml of water, after which 0.43 ml of 1N aqueous hydrochloric acid was added. The resulting mixture was worked up and purified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque), using water as the eluent. Those fractions containing the title compound were combined and lyophilized to give 149 mg of the title compound as a powder.
後処理
- custompurified by reverse phase column chromatography through 30 ml of Cosmo Sil 75C18 -PREP (a trade mark for a product of Nacalai Tesque),
- additionThose fractions containing the title compound
出典と根拠
- ORDレコード
- ord-55c916a8c719440daef285ba638a7e8e
- 出典データセット
- uspto-grants-1998_01
- 特許番号
- US05712267
反応ノート
読み込み中…